Ipilimumab improves clinical outcomes when combined with nivolumab in early-stage, operable non-small cell lung cancer. In a first for a neoadjuvant trial, the study also found that responsiveness to the dual checkpoint blockade strategy may be influenced by a patient's gut microbiome.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.